Company Encyclopedia
View More
name
Shen Lian Biomedical
688098.SH
Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. It develops synthetic peptide vaccines to treat foot-and-mouth diseases. The company was founded in 2001 and is headquartered in Shanghai, China.
3.196 T
688098.SHMarket value -Rank by Market Cap -/-

Financial Score

07/11/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking155/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-2.11%D
    • Profit Margin-10.36%D
    • Gross Margin60.22%A
  • Growth ScoreD
    • Revenue YoY-5.66%D
    • Net Profit YoY-53.76%D
    • Total Assets YoY-1.37%D
    • Net Assets YoY-3.71%D
  • Cash ScoreD
    • Cash Flow Margin-965.17%E
    • OCF YoY-5.66%D
  • Operating ScoreD
    • Turnover0.19D
  • Debt ScoreA
    • Gearing Ratio8.94%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Shen Lian Biomedical released its performance for the first three quarters, with a net profit attributable to the parent company of 280,000 yuan, turning a profit compared to the same period last year

    According to the Zhitong Finance APP, Shen Lian Biomedical disclosed its third-quarter report for 2025. The company achieved revenue of 238 million yuan in the first three quarters, a year-on-year decrease of 4.27%; the net profit attributable to the parent company was 280,000 yuan, turning from a loss to a profit year-on-year; the net profit excluding non-recurring items was a loss of 5.1 million yuan; the basic earnings per share were 0 yuan

    Zhitong·
    SH
    688098
    -0.73%
    Zhitong·
    SH
    688098
    -0.73%

    Shen Lian Biomedical: UBI plans to reduce its holdings by no more than 3% of shares

    Shen Lian Biomedical announced that United BioPharma, Inc. (UBI) plans to reduce its holdings by no more than 3% within the next three months to raise funds for the clinical trials and commercialization of an Alzheimer's vaccine. The specific reduction methods include reducing 4.1064 million shares through centralized bidding and reducing 8.2129 million shares through block trading

    Zhitong·
    SH
    688098
    -0.73%
    Zhitong·
    SH
    688098
    -0.73%

    Innovative drug concept stocks continue to be active, HUAPONT LIFE SCIENCES hits the limit up

    Innovative drug concept stocks continue to be active, HUAPONT LIFE SCIENCES hits the limit up, Shen Lian Biomedical, Staidson BioPharm, CISEN, and WECOME follow suit

    Zhitong·
    SZ
    300683
    -0.52%
    SZ
    002004
    +2.02%
    SH
    688098
    -0.73%
    Zhitong·
    SZ
    300683
    -0.52%
    SZ
    002004
    +2.02%
    SH
    688098
    -0.73%

    Shen Lian Biomedical has been approved for a veterinary drug product approval number

    Shen Lian Biomedical has been approved to produce a bivalent inactivated vaccine for swine streptococcosis and infectious pleuropneumonia, with the approval number issued by the Ministry of Agriculture and Rural Affairs. This product will enhance the company's product matrix for veterinary bacterial disease prevention and control, improve capacity utilization, and provide a more comprehensive epidemic prevention and control solution

    Zhitong·
    SH
    688098
    -0.73%
    Zhitong·
    SH
    688098
    -0.73%

    Shen Lian Biomedical: The Phase II clinical study of the innovative drug UB-221 injection has completed the enrollment of all subjects

    On August 31, Shen Lian Biomedical announced that its investee company, Shizhiyuan, has completed the enrollment of 145 subjects in the Phase II clinical study of the innovative drug UB-221 injection. The marketing authorization and commercialization rights of UB-221 in mainland China are owned by Shizhiyuan. This drug is developed by United Biomedical, Inc. in the United States and is a subcutaneous injection formulation of a humanized original monoclonal antibody targeting anti-IgE therapy

    Zhitong·
    SH
    688098
    -0.73%
    Zhitong·
    SH
    688098
    -0.73%